Symbols

LGVN

Longeveron·NASDAQ

--(--)

LGVN fundamentals

LGVN Q4 2025 Earnings

Longeveron (LGVN) released its earnings on Mar 17, 2026: revenue was 365.00K (YoY -39.47%), beat estimates; EPS was -0.23 (YoY +46.98%), beat estimates.

Revenue / YoY

365.00K

-39.47%

EPS / YoY

-0.23

+46.98%

Report date

Mar 17, 2026

LGVN Earnings Call Summary for Q4,2025

$15M Capital Raise: Secured institutional backing for HLHS BLA preparation and strategic partnerships.
PRV Potential: HLHS PRV sale proceeds split 50/50; PDCM PRV retained for $150-205M+ value.
Clinical Momentum: ELPIS-II results Q3 2026; PDCM trial planning for 2027.
Financial Update: 2025 net loss $22.7M, but $15.9M March 2026 raise extends runway to Q4 2026.
Strategic Focus: Licensing Alzheimer’s/FSD, CDMO manufacturing, and PRV monetization.

Earnings

EPS

Revenue

Revenue & Expenses

LGVN has released its 2025 Q4 earnings report, with revenue of 365.00K, reflecting a YoY change of -39.47%, and net profit of -5.44M, showing a YoY change of -33.40%. The Sankey diagram below clearly presents LGVN's revenue sources and cost distribution.

Key Indicators

Longeveron (LGVN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Longeveron (LGVN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Longeveron (LGVN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Longeveron (LGVN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown